Register a trial

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06335303




Registration number
NCT06335303
Ethics application status
Date submitted
22/03/2024
Date registered
28/03/2024

Titles & IDs
Public title
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Scientific title
A Randomised, Double-blind, Placebo-controlled, Dose-finding Study Evaluating Efficacy, Safety, and Tolerability of Different Oral Doses of BI 1819479 Over at Least 24 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Secondary ID [1] 0 0
2023-508395-11-00
Secondary ID [2] 0 0
1462-0004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BI 1819479
Treatment: Drugs - Placebo matching BI 1819479

Experimental: BI 1819479 low dose treatment group -

Experimental: BI 1819479 medium dose treatment group -

Experimental: BI 1819479 high dose treatment group -

Placebo comparator: Placebo group -


Treatment: Drugs: BI 1819479
BI 1819479

Treatment: Drugs: Placebo matching BI 1819479
Placebo matching BI 1819479
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annual rate of decline in Forced Vital Capacity (FVC) [milliLiter/year]
Assessment method [1] 0 0
Timepoint [1] 0 0
Up to 52 weeks
Secondary outcome [1] 0 0
Absolute change from baseline in FVC at Week 24 [in milliLiter]
Assessment method [1] 0 0
Timepoint [1] 0 0
At baseline and at week 24

Eligibility
Key inclusion criteria
1. Patients =40 years old at the time of signed informed consent.
2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
3. Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
4. On stable treatment with nintedanib or pirfenidone for at least 12 weeks or not on treatment with either nintedanib or pirfenidone for at least 12 weeks
5. Forced Vital Capacity (FVC) =45% of predicted normal.
6. Diffusion capacity of the lung for carbon monoxide (DLCO) =25% of predicted normal corrected for hemoglobin (Hb).
7. Women of childbearing potential (WOCBP) must use highly effective methods of birth control with low user dependency and additional barrier contraception for male partners (use of condom) until end of follow-up period.
8. Male trial participants with WOCBP partners must use contraception (condom) to avoid exposure via seminal fluid. Female partners of male trial participants must use highly effective methods of contraception during treatment until end of follow-up period.
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) within at least 12 weeks prior to screening and/or during the screening period (investigator-determined).
2. Treated with immunosuppressive medications (other than oral corticosteroids) or prednisone >15 mg/day or equivalent for respiratory or pulmonary reasons.
3. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
4. The patient is currently enrolled in another investigational device or drug trial, or their Visit 1 occurs less than 30 days or 5 half-lives (whichever is longer) after completing a previous investigational device or drug trial or receiving other investigational treatments.
5. Patients with a significant disease or condition other than the IPF under study, which in the opinion of the investigator, may put the patient at risk because of participation, interfere with trial procedures, or cause concern regarding the patient's ability to participate in the trial or any medical condition which could lead to a life expectancy <12 months.
6. Relevant airways obstruction (pre-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <0.7).
7. In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
8. Lower respiratory tract infection requiring treatment within 4 weeks prior to Visit 1 and/or during the screening period.

Further exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/09/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
21/07/2026
Actual
Sample size
Target
300
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Lung Research Victoria - Footscray
Recruitment hospital [3] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [4] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [5] 0 0
Institute for Respiratory Health - Nedlands
Recruitment hospital [6] 0 0
Macquarie University - Macquarie Park
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3011 - Footscray
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment postcode(s) [6] 0 0
2109 - Macquarie Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Iowa
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
Mississippi
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
South Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Utah
Country [11] 0 0
Argentina
State/province [11] 0 0
C.a.b.a
Country [12] 0 0
Argentina
State/province [12] 0 0
Caba
Country [13] 0 0
Argentina
State/province [13] 0 0
Capital Federal
Country [14] 0 0
Austria
State/province [14] 0 0
Graz
Country [15] 0 0
Austria
State/province [15] 0 0
Krems
Country [16] 0 0
Austria
State/province [16] 0 0
Linz
Country [17] 0 0
Austria
State/province [17] 0 0
Vienna
Country [18] 0 0
Austria
State/province [18] 0 0
Wels
Country [19] 0 0
Belgium
State/province [19] 0 0
Bruxelles
Country [20] 0 0
Belgium
State/province [20] 0 0
Liège
Country [21] 0 0
Brazil
State/province [21] 0 0
Barra Mansa
Country [22] 0 0
Brazil
State/province [22] 0 0
Goiania
Country [23] 0 0
Brazil
State/province [23] 0 0
Porto Alegre
Country [24] 0 0
Canada
State/province [24] 0 0
Alberta
Country [25] 0 0
Canada
State/province [25] 0 0
Nova Scotia
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
China
State/province [27] 0 0
Beijing
Country [28] 0 0
China
State/province [28] 0 0
Changsha
Country [29] 0 0
China
State/province [29] 0 0
Chengdu
Country [30] 0 0
China
State/province [30] 0 0
Guangzhou
Country [31] 0 0
China
State/province [31] 0 0
Hangzhou
Country [32] 0 0
China
State/province [32] 0 0
Hefei
Country [33] 0 0
China
State/province [33] 0 0
Nanjing
Country [34] 0 0
China
State/province [34] 0 0
Shenyang
Country [35] 0 0
China
State/province [35] 0 0
Tianjin
Country [36] 0 0
China
State/province [36] 0 0
Wuhan
Country [37] 0 0
China
State/province [37] 0 0
Xuzhou
Country [38] 0 0
Czechia
State/province [38] 0 0
Prague
Country [39] 0 0
Denmark
State/province [39] 0 0
København Ø
Country [40] 0 0
Denmark
State/province [40] 0 0
Odense
Country [41] 0 0
Finland
State/province [41] 0 0
Helsinki
Country [42] 0 0
Finland
State/province [42] 0 0
Oulu
Country [43] 0 0
Finland
State/province [43] 0 0
Tampere
Country [44] 0 0
Finland
State/province [44] 0 0
Turku
Country [45] 0 0
France
State/province [45] 0 0
Angers
Country [46] 0 0
France
State/province [46] 0 0
Bron
Country [47] 0 0
France
State/province [47] 0 0
Caen
Country [48] 0 0
France
State/province [48] 0 0
Lille
Country [49] 0 0
France
State/province [49] 0 0
Marseille
Country [50] 0 0
France
State/province [50] 0 0
Nice
Country [51] 0 0
France
State/province [51] 0 0
Rennes
Country [52] 0 0
France
State/province [52] 0 0
Rouen
Country [53] 0 0
Germany
State/province [53] 0 0
Bonn
Country [54] 0 0
Germany
State/province [54] 0 0
Donaustauf
Country [55] 0 0
Germany
State/province [55] 0 0
Fulda
Country [56] 0 0
Germany
State/province [56] 0 0
Greifswald
Country [57] 0 0
Germany
State/province [57] 0 0
Hannover
Country [58] 0 0
Germany
State/province [58] 0 0
Immenhausen
Country [59] 0 0
Germany
State/province [59] 0 0
Konstanz
Country [60] 0 0
Germany
State/province [60] 0 0
Leipzig
Country [61] 0 0
Germany
State/province [61] 0 0
München
Country [62] 0 0
Greece
State/province [62] 0 0
Voutes
Country [63] 0 0
Hungary
State/province [63] 0 0
Budapest
Country [64] 0 0
Hungary
State/province [64] 0 0
Debrecen
Country [65] 0 0
Italy
State/province [65] 0 0
Firenze
Country [66] 0 0
Italy
State/province [66] 0 0
Milano
Country [67] 0 0
Italy
State/province [67] 0 0
Padova
Country [68] 0 0
Italy
State/province [68] 0 0
Roma
Country [69] 0 0
Japan
State/province [69] 0 0
Fukui, Yoshida-gun
Country [70] 0 0
Japan
State/province [70] 0 0
Fukuoka, Fukuoka
Country [71] 0 0
Japan
State/province [71] 0 0
Kanagawa, Yokohama
Country [72] 0 0
Japan
State/province [72] 0 0
Osaka, Sakai
Country [73] 0 0
Japan
State/province [73] 0 0
Shizuoka, Hamamatsu
Country [74] 0 0
Japan
State/province [74] 0 0
Tokushima, Tokushima
Country [75] 0 0
Japan
State/province [75] 0 0
Tokyo, Mitaka
Country [76] 0 0
Japan
State/province [76] 0 0
Tokyo, Ota-ku
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Bucheon
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Busan
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Seongnam
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Seoul
Country [81] 0 0
Malaysia
State/province [81] 0 0
Kuala Lumpur
Country [82] 0 0
New Zealand
State/province [82] 0 0
Hamilton
Country [83] 0 0
New Zealand
State/province [83] 0 0
One Tree Hill, Auckland
Country [84] 0 0
Norway
State/province [84] 0 0
Bergen
Country [85] 0 0
Norway
State/province [85] 0 0
Lørenskog
Country [86] 0 0
Poland
State/province [86] 0 0
Bialystok
Country [87] 0 0
Poland
State/province [87] 0 0
Lodz
Country [88] 0 0
Poland
State/province [88] 0 0
Poznan
Country [89] 0 0
Poland
State/province [89] 0 0
Swidnik
Country [90] 0 0
Poland
State/province [90] 0 0
Warsaw
Country [91] 0 0
Singapore
State/province [91] 0 0
Singapore
Country [92] 0 0
Spain
State/province [92] 0 0
Alicante
Country [93] 0 0
Spain
State/province [93] 0 0
Barcelona
Country [94] 0 0
Spain
State/province [94] 0 0
Galdakao
Country [95] 0 0
Spain
State/province [95] 0 0
L'Hospitalet de Llobregat
Country [96] 0 0
Spain
State/province [96] 0 0
Madrid
Country [97] 0 0
Spain
State/province [97] 0 0
Malaga
Country [98] 0 0
Spain
State/province [98] 0 0
Oviedo
Country [99] 0 0
Spain
State/province [99] 0 0
Santander
Country [100] 0 0
Spain
State/province [100] 0 0
Sevilla
Country [101] 0 0
Sweden
State/province [101] 0 0
Stockholm
Country [102] 0 0
Sweden
State/province [102] 0 0
Uppsala
Country [103] 0 0
Taiwan
State/province [103] 0 0
Kaohsiung
Country [104] 0 0
Taiwan
State/province [104] 0 0
Taichung
Country [105] 0 0
Taiwan
State/province [105] 0 0
Taipei
Country [106] 0 0
Taiwan
State/province [106] 0 0
TaoYuan
Country [107] 0 0
Thailand
State/province [107] 0 0
Bangkok
Country [108] 0 0
Thailand
State/province [108] 0 0
Hat Yai
Country [109] 0 0
Thailand
State/province [109] 0 0
Khon Kaen
Country [110] 0 0
Thailand
State/province [110] 0 0
Ratchathewi
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Birmingham
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Cottingham, Hull
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Exeter
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Lancaster
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Leeds
Country [116] 0 0
United Kingdom
State/province [116] 0 0
London
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Manchester
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Boehringer Ingelheim
Address 0 0
Country 0 0
Phone 0 0
1-800-243-0127
Email 0 0
clintriage.rdg@boehringer-ingelheim.com
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06335303